Irritable bowel syndrome with constipation: antidepressants
Tricyclic antidepressants (TCAs) are recommended for the treatment of global IBS symptoms (Class I, Level A in the ACG guideline). [1]
TCAs used in IBS include amitriptyline, imipramine, desipramine, and nortriptyline. [1]
TCAs should be initiated at low doses with gradual titration to minimize adverse effects. [1]
Irritable bowel syndrome with constipation: key TCA dosing targets
Low-dose initiation strategies are supported, including starting with approximately 10 mg of amitriptyline or desipramine followed by gradual dose titration. [1]
Irritable bowel syndrome with constipation: antispasmodic agents
Antispasmodics are suggested for IBS symptom management (AGA: suggested over no drug treatment). [2]
In the United States, ACG does not recommend routine use of antispasmodics currently available to treat global IBS symptoms (conditional recommendation; low quality of evidence). [1]
The US antispasmodics discussed in ACG include dicyclomine, hyoscyamine, and hyoscine (scopolamine). [1]
Irritable bowel syndrome with constipation: peppermint oil
Peppermint is suggested for relief of global IBS symptoms (ACG: conditional recommendation; low quality of evidence). [1]
For global IBS symptoms, peppermint oil produced an overall relative risk (RR) of persistent symptoms of 2.39 vs placebo in meta-analysis data cited in the ACG guideline. [1]
For abdominal pain, peppermint oil produced an RR of 1.78 vs placebo in meta-analysis data cited in the ACG guideline. [1]
The number needed to treat to prevent persistent overall IBS symptoms was 3 and the number needed to treat to prevent persistent abdominal pain was 4 in the meta-analysis data cited in the ACG guideline. [1]
Initiation sequencing relevant to constipation-predominant IBS
TCAs are considered after failure of laxatives, loperamide, or antispasmodics in the NICE IBS management pathway (TCAs as second-line therapy for IBS-related symptoms). [3]
Antispasmodics are recommended to be considered in the NICE IBS management pathway. [3]
Agent-specific efficacy and tolerability signals for antispasmodics
Dicyclomine showed symptom improvement in small older trials but had a higher adverse effect rate than placebo in the ACG guideline summary, including 69% vs 16% in one study and 33% vs 4% in a second study. [1]
Hyoscyamine showed adverse effect rates significantly higher than placebo (87% vs 7%) in the single older study summarized in the ACG guideline. [1]
Hyoscine (scopolamine) data summarized in the ACG guideline were largely outside the United States and included mixed outcomes with adverse effects such as dry mouth and blurred vision. [1]
Practical selection: aligning antidepressants with pain-predominant IBS-C
TCAs are selected to address IBS pain through neuromodulator effects used in chronic pain syndromes, as described in the ACG guideline. [1]
Antispasmodic selection is limited by the low-quality and sparse efficacy evidence for US-available agents in the ACG guideline and by tolerability concerns documented in older trials. [1]
Peppermint oil is supported as an antispasmodic-like option with symptom and pain efficacy signals in meta-analysis data summarized in the ACG guideline. [1]